CA1337124C - Derives de flavolignane; methode pour les preparer; compositions pharmaceutiques a base de ces derives - Google Patents

Derives de flavolignane; methode pour les preparer; compositions pharmaceutiques a base de ces derives

Info

Publication number
CA1337124C
CA1337124C CA000495804A CA495804A CA1337124C CA 1337124 C CA1337124 C CA 1337124C CA 000495804 A CA000495804 A CA 000495804A CA 495804 A CA495804 A CA 495804A CA 1337124 C CA1337124 C CA 1337124C
Authority
CA
Canada
Prior art keywords
silibinin
independently selected
alk2
alk1
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000495804A
Other languages
English (en)
Inventor
Reinhard Braatz
Klaus Gorler
Gunter Halbach
Hartwig Soicke
Karlheinz Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madaus Holding GmbH
Original Assignee
Madaus AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madaus AG filed Critical Madaus AG
Application granted granted Critical
Publication of CA1337124C publication Critical patent/CA1337124C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Silicon Compounds (AREA)
CA000495804A 1984-11-22 1985-11-20 Derives de flavolignane; methode pour les preparer; compositions pharmaceutiques a base de ces derives Expired - Fee Related CA1337124C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3442639 1984-11-22
DE19843442639 DE3442639A1 (de) 1984-11-22 1984-11-22 Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten

Publications (1)

Publication Number Publication Date
CA1337124C true CA1337124C (fr) 1995-09-26

Family

ID=6250903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000495804A Expired - Fee Related CA1337124C (fr) 1984-11-22 1985-11-20 Derives de flavolignane; methode pour les preparer; compositions pharmaceutiques a base de ces derives

Country Status (29)

Country Link
JP (1) JPS61143377A (fr)
KR (1) KR870001020B1 (fr)
AR (1) AR240931A1 (fr)
AT (1) AT393268B (fr)
BE (1) BE903693A (fr)
CA (1) CA1337124C (fr)
CH (1) CH659473A5 (fr)
CS (1) CS273610B2 (fr)
DD (1) DD259191A1 (fr)
DE (1) DE3442639A1 (fr)
DK (1) DK164865C (fr)
EG (1) EG19424A (fr)
ES (1) ES8609311A1 (fr)
FI (1) FI84064C (fr)
FR (1) FR2573427B1 (fr)
GB (1) GB2167414B (fr)
HU (1) HU195503B (fr)
IE (1) IE58791B1 (fr)
IT (1) IT1190426B (fr)
LU (1) LU86163A1 (fr)
MX (1) MX168415B (fr)
NL (1) NL192387C (fr)
NO (1) NO160205C (fr)
PL (1) PL146890B1 (fr)
PT (1) PT81532B (fr)
SE (1) SE465676B (fr)
SU (1) SU1436875A3 (fr)
YU (1) YU43689B (fr)
ZA (1) ZA858951B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008361A2 (fr) 2012-07-05 2014-01-09 Nutramax Laboratories, Inc. Compositions comprenant un sulforaphane ou un précurseur de sulforaphane et un extrait ou une poudre de chardon marie

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716918D0 (en) * 1987-07-17 1987-08-26 Inverni Della Beffa Spa Soluble derivatives of silybin
US5262439A (en) * 1992-04-30 1993-11-16 The Regents Of The University Of California Soluble analogs of probucol
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
RU2482844C2 (ru) * 2007-11-15 2013-05-27 Мадаус Гмбх Силибининовый компонент для лечения гепатита
MX2010005107A (es) * 2007-11-15 2010-05-27 Madaus Gmbh Componente de silibinina para tratamiento contra hepatitis.
CA2761656C (fr) 2009-05-14 2017-02-07 Lucio Claudio Rovati Silibinine amorphe pour le traitement d'une hepatite virale
CN103172622B (zh) * 2013-02-22 2015-11-04 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯的活性异构体
CN103193768B (zh) * 2013-02-22 2016-03-30 西安安健药业有限公司 治疗肝病的水飞蓟宾二偏琥珀酸酯异构体
CN103113359B (zh) * 2013-02-22 2016-01-06 西安安健药业有限公司 水飞蓟宾二偏琥珀酸酯及其药用盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963318A1 (de) * 1969-12-17 1971-06-24 Schwabe Willmar Gmbh & Co Silybinhalbester der Bernsteinsaeure und der Phthalsaeure,ihre Salze mit pharmakologisch vertraglichen Basen,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008361A2 (fr) 2012-07-05 2014-01-09 Nutramax Laboratories, Inc. Compositions comprenant un sulforaphane ou un précurseur de sulforaphane et un extrait ou une poudre de chardon marie
EP3409280A1 (fr) 2012-07-05 2018-12-05 Nutramax Laboratories, Inc. Compositions comprenant un sulforaphane et un extrait ou poudre de chardon-marie
EP3821895A1 (fr) 2012-07-05 2021-05-19 Nutramax Laboratories, Inc. Compositions comprenant du sulforaphane ou un extrait de brocoli et un extrait ou une poudre de chardon-marie

Also Published As

Publication number Publication date
ZA858951B (en) 1986-08-27
YU178685A (en) 1988-02-29
PT81532B (pt) 1987-11-11
FI854535A0 (fi) 1985-11-18
DK537785D0 (da) 1985-11-21
NL192387B (nl) 1997-03-03
DK164865C (da) 1993-01-18
SE8505487D0 (sv) 1985-11-20
LU86163A1 (de) 1986-03-24
CS273610B2 (en) 1991-03-12
EG19424A (en) 1995-02-28
FR2573427A1 (fr) 1986-05-23
IE58791B1 (en) 1993-11-17
CS837885A2 (en) 1990-08-14
PT81532A (de) 1985-12-01
BE903693A (fr) 1986-05-22
CH659473A5 (de) 1987-01-30
IE852808L (en) 1986-05-22
SE8505487L (sv) 1986-05-23
NO160205C (no) 1989-03-22
AT393268B (de) 1991-09-25
FR2573427B1 (fr) 1989-03-10
KR860004056A (ko) 1986-06-16
NL192387C (nl) 1997-07-04
ATA337185A (de) 1991-02-15
GB2167414A (en) 1986-05-29
HU195503B (en) 1988-05-30
DK537785A (da) 1986-05-23
HUT40114A (en) 1986-11-28
IT1190426B (it) 1988-02-16
ES8609311A1 (es) 1986-09-01
GB8528226D0 (en) 1985-12-18
MX168415B (es) 1993-05-24
NO160205B (no) 1988-12-12
YU43689B (en) 1989-10-31
ES549116A0 (es) 1986-09-01
DD259191A1 (de) 1988-08-17
NO854655L (no) 1986-05-23
NL8503171A (nl) 1986-06-16
PL256374A1 (en) 1986-12-02
DE3442639A1 (de) 1986-05-22
PL146890B1 (en) 1989-03-31
SE465676B (sv) 1991-10-14
SU1436875A3 (ru) 1988-11-07
IT8522932A0 (it) 1985-11-21
JPS61143377A (ja) 1986-07-01
FI84064B (fi) 1991-06-28
KR870001020B1 (ko) 1987-05-23
GB2167414B (en) 1989-01-11
AR240931A1 (es) 1991-03-27
FI854535A (fi) 1986-05-23
FI84064C (fi) 1991-10-10
AR240931A2 (es) 1991-03-27
DE3442639C2 (fr) 1989-08-10
JPH0432073B2 (fr) 1992-05-28
DK164865B (da) 1992-08-31

Similar Documents

Publication Publication Date Title
CA1337124C (fr) Derives de flavolignane; methode pour les preparer; compositions pharmaceutiques a base de ces derives
FI84065B (fi) Foerfarande foer framstaellning av isosilybinfri silibinin.
Hosford et al. Natural antagonists of platelet‐activating factor
JP5403844B2 (ja) ＡｎｔｒｏｄｉａＣａｍｐｈｏｒａｔａの菌糸体から得た新規な混合物及び化合物、並びにその使用
JPH0778021B2 (ja) 下痢症ウイルス感染阻害剤
JPH10287617A (ja) 新規ジテルペン類及びジテルペン類を有効成分とする抗ウイルス剤
CN101829094B (zh) E环溴取代水飞蓟宾用于制备治疗病毒性乙肝药物的用途
US4883813A (en) Method of treating inflammation in mammals utilizing ketobutyrolactones and furylbutyrolactones
KR100542323B1 (ko) 후박나무로부터 세포사멸 유도작용을 갖는 화합물을 분리하는 방법
KR100831645B1 (ko) 항고지혈, 항산화 및 항바이러스 활성을 갖는 참취 추출물및 그로부터 분리된 화합물
CN101829096B (zh) E环碘取代水飞蓟宾用于制备治疗病毒性乙肝药物的用途
SI8511786A8 (sl) Postopek za pripravo derivatov silibinina
RU2178709C2 (ru) Способ получения вещества, обладающего иммуномодулирующей активностью
Yusupova et al. New Source Of Synthesis Of Physiologically Active Substonces
RU2018315C1 (ru) Способ получения полифенолов, обладающих гепатозащитной, желчегонной, антиоксидантной и аналептической активностью
JPH03157347A (ja) オクタデセン酸誘導体及びこれを有効成分とする子宮頚癌細胞の殺細胞剤
JPH03120217A (ja) ジヒドロベンゾフラン誘導体を有効成分とする消化器系疾患予防治療剤
CN101912383B (zh) E环去甲氧水飞蓟宾用于制备治疗病毒性乙肝药物的用途
KR20000051921A (ko) 약학 조성물
KR20020084333A (ko) 역전사효소 저해활성을 갖는 옻나무 추출물
JPH0892079A (ja) ヒスタミン遊離抑制剤
JPH0426698A (ja) 新規フラバノン配糖体またはフラバノン配糖体および不飽和脂肪酸アミド化合物を有効成分とする抗アレルギー剤

Legal Events

Date Code Title Description
MKLA Lapsed